Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor T cells are T cells genetically engineered with CAR constructs which mainly contain scFV and TCR zeta chain. With promising development in blood cancers, CAR T trials are also applied in solid cancers. However, the treatment effect in solid cancers is lower than expected. This review summarizes difference of CAR T applications in solid and blood cancers. Future challenges of CAR T cell treatment in solid cancer are also discussed using ovarian cancer as an example.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: